Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 31 n° 259

Posts Tagged ‘treatment’

Low control for high cholesterol

Posted by fidest press agency su mercoledì, 2 febbraio 2011

The largest ever study – representing 147 million people – shows that most people with high cholesterol levels are not getting the treatment they need to reduce their risk of cardiovascular disease such as heart attack and stroke. Many of these people – living in England, Germany, Japan, Jordan, Mexico, Scotland, Thailand and the United States of America – are unaware that they need treatment, which is easily accessible in the form of low-cost medicines. This study, published today in the international public health journal, the Bulletin of the World Health Organization, is the first to show the extent of the treatment gap for high cholesterol – a common risk factor for early cardiovascular deaths. In Thailand, for example, 78% of adults surveyed had not been diagnosed, while in Japan, 53% of adults were diagnosed but remained untreated.
http://www.who.int/bulletin/volumes/89/02/10-079947.pdf
The Bulletin of the World Health Organization is one of the world’s leading public health journals. It is the flagship periodical of WHO, with a special focus on developing countries. Articles are peer-reviewed and are independent of WHO guidelines. Abstracts are now available in the six official languages of the United Nations. Further items in this month’s issue include:
•    What is the ideal weight gain during pregnancy? A study from Viet Nam
•    Modern contraceptive use in Africa stagnates
•    Radio programme helps combat food insecurity
•    Why so slow to develop new antibiotics?
•    Diabetes – a product of modern technology

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »

Children: Medically assisted reproduction

Posted by fidest press agency su mercoledì, 9 giugno 2010

Children conceived by Medically Assisted Reproduction (MAR) have fiscal implications for government both in terms of future government spending and tax revenue. Based on public funding to conceive a MAR child – after factoring in education, future health and pension costs, and future tax contributions of this child – the discounted net tax revenue (the difference between future government spending and tax revenue) of a child born in 2005 is roughly €127,000 in today’s value. Considering an average treatment cost of approximately €15,000 to conceive an IVF-child, this represents an 8-fold return on investment (ROI) for governments. While the costs of MAR treatment represent a substantial proportion of a patient’s annual disposable income, MAR typically represents less than 0.25% of total national healthcare expenditure. By comparison, obesity accounts for 10% and 2-4% of total health care spending in the US and Europe respectively. MAR treatments elicit significant medical, reproductive and economic influence in developed countries with 3.5 million children estimated to have been born worldwide since 1978. These children make up a substantial proportion of national births with up to 4.1% in Denmark and 3.3% in Belgium. In the US, Europe, and Oceania over 600,000 treatment cycles resulted in 120,000 children being born in 2005. The European Society of Human Reproduction and Embryology (ESHRE) Task Force on ‘Reproduction and Society’ reviewed the economics of MAR to evaluate the benefits of funding of MAR for society and to inform policy makers on effective, safe and equitable financing of MAR. Dr. Mark Connolly and colleagues who published this review paper in the journal Human Reproduction Update based their findings on key epidemiological and economic studies. The authors conclude that the way MAR is subsidised in different healthcare settings and for different patient groups has far-reaching consequences for access to treatment, clinical practice, and infant outcomes. MAR children deserve the best start in life, and as discussed in this review, affordable treatment can make economic sense as well.ESHRE was founded in 1985 with a mission is to promote the understanding of reproductive science and medicine. It does this through facilitating research and the dissemination of research findings in human reproduction and embryology to the general public, scientists, clinicians, patient associations and key policy makers across Europe. Human Reproduction and Human Reproduction Update are monthly journals of ESHRE, and are published by Oxford Journals, a division of Oxford University Press. For more information visit ESHRE’s website at http://www.eshre.eu.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Drug resistant tuberculosis levels

Posted by fidest press agency su martedì, 25 agosto 2009

Ten times higher in eastern Europe and central Asia Tuberculosis patients in parts of Eastern Europe and Central Asia are 10 times more likely to have multidrug-resistant TB (MDR-TB) than in the rest of the world, according to a World Health Organization (WHO) report into the deadly infectious disease. China, Ecuador, Israel and South Africa are also identified as key areas. New data released today confirm geographical concentrations of TB drug resistance across the Commonwealth of Independent States. Six out of the top ten global hotspots are: Estonia, Kazakhstan, Latvia, Lithuania, parts of the Russian Federation and Uzbekistan, with drug resistance in new patients as high as 14%. According to the report “the most effective strategy to prevent the emergence of drug resistance is through implementation of the DOTS.” DOTS is the internationally agreed treatment strategy, and is designed to ensure patients take their medicines properly. It has proven effective in preventing drug resistance. Research and development into new TB drugs is also urgently required to shorten the length of treatment and to treat drug resistant strains. After a 40 year standstill in TB drug development, R&D investments are critical now to expand treatment options and overcome resistant strains. The Global Alliance for TB Drug Development, a WHO partner, is building a pipeline of promising new drugs and uniting public and private researchers in the search for a faster cure.  “Anti-Tuberculosis Drug Resistance in the World – Third Global Report” presents data from the examination of 67 657 TB patients in 77 countries and regions. “The more we survey, the more MDR-TB we find,” said the report’s leading author Dr Mohamed Aziz. “MDR TB has now been identified in every region and almost every country surveyed in what is the largest drug resistance surveillance project of its kind. Yet the true burden is unknown and may well be higher in unsurveyed areas, stressing the need for full expansion of drug resistance surveillance.”

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

To treat chronic lymphocytic leukemia

Posted by fidest press agency su giovedì, 13 agosto 2009

Copenhagen, Denmark Genmab A/S (OMX: GEN) announced top-line results from the Phase II study of Arzerra(TM) (ofatumumab) in combination with fludarabine and cyclophosphamide (FC) to treat chronic lymphocytic leukemia (CLL) in previously untreated patients. A total of 61 patients were treated in the study. Treatment response was assessed using the 1996 National Cancer Institute Guidelines. The complete remission rate was 32% in patients who received 500 mg of ofatumumab (n=31) and 50% in patients who received 1000 mg of ofatumumab (n=30). The overall response rate was 77% in the 500 mg treatment group and 73% in the 1000 mg treatment group.There were no unexpected safety findings reported during treatment and within 30 days after last infusion. The most common adverse event reported was neutropenia at 48%. Other common adverse events (greater that 15 percent) were nausea, leukopenia, rash, vomiting, pyrexia, headache and thrombocytopenia. The number of patients, who experienced adverse events, including serious adverse events, was similar between the two dose groups. One death was reported and was judged by the investigator as unrelated to ofatumumab. Patients in this open label study were randomized into two treatment groups. Each patient was to receive one infusion of 300 mg of ofatumumab in combination with FC followed by 5 monthly infusions of either 500 or 1000 mg of ofatumumab in combination with FC. Disease status was measured every 4 weeks until week 24 and every 3 months thereafter until disease progression or 24 months. Treatment response was assessed according to the 1996 National Cancer Institute Working Group guidelines by an Independent endpoints Review Committee. Patients nothaving progressed on their disease at 24 months will be followed for disease progression at 6 month intervals until 60 months.The objective of the study was to determine the efficacy of ofatumumab in combination with FC in previously untreated CLL patients. The primary endpoint was complete remission rate from start of treatment until 3 months aftelast infusion. Ofatumumab is a novel, investigational, fully human monoclonal antibody that targets a membrane-proximal (close to the cell surface) small loop epitope (a portion of a molecule to which an antibody binds) on the CD20 molecule of B-cells. This epitope is different from the binding sites targeted by other CD20 antibodies currently available.The CD20 molecule is a key target in CLLtherapy because it is expressed on most B-cells in CLL patients. Ofatumumab is being developed under a co-development and commercialization agreement between Genmab and GlaxoSmithKline. It is not yet approved in any country http://www.genmab.com Genma is a leading international biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer. Genmab’s world class discovery, development and manufacturing teams are using cutting-edge technology to create and develop products to address unmet medical needs. Our primary goal is to improve the lives of patients who are in urgent need of new treatment options. For more information on Genmab’s products and technology, visit

Posted in Estero/world news, Medicina/Medicine/Health/Science | Contrassegnato da tag: , , , | Leave a Comment »

Congo Church launches $144 million programme for AIDS

Posted by fidest press agency su martedì, 19 maggio 2009

The Catholic Church in the Democratic Republic of Congo has pledged to collect funds of US$ 144 million for a three-year HIV and AIDS programme. The funds will be used by Caritas Congo to provide education and prevention, treatment and care, and also work against stigma.  As many as 450,000 people are living with HIV in Congo as of 2007, with as many as 50,000 children infected by the virus.  Conflict in the east of the country in which around 1.5 million people have fled their homes has left women and children vulnerable to rape and AIDS infection. As many as 27,000 sexual assaults were reported in 2006 in South Kivu Province alone and 10-12 percent of women raped are infected with HIV. The three-year programme is a collaborative effort and has been drafted with the participation of 47 dioceses in the country. The widespread network of the Church on a local level in Congo means that it has access to communities which don’t have a solid health infrastructure.  Caritas Congo’s Director Dr Bruno Miteyo presented the programme at a conference of Congo’s bishops in Kinshasa last week. He said that millions of Congolese affected by the pandemic will benefit.  Congo’s Government said at the meeting that faith-based organisations like the Church had a strong role to play and affirmed a joint commitment to tackle the pandemic.

Posted in Estero/world news | Contrassegnato da tag: , , , | 1 Comment »